Abiopharma

Sherritt Announces Exclusivity Agreement with Gillon Capital and Appointment of Independent Director

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Electronic Arts Introduces EA Advertising, Launching Brands Directly Into Gameplay and Live Experiences

Surge Copper Announces Results of Berg Pre-Feasibility Study with After-Tax NPV8% of C$4.6 billion and 24% IRR

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Sable Expands the Zorro Project Through New Staking and an Option Agreement of the El Acero Property, San Juan, Argentina

Lightbridge to Participate in Upcoming Investor and Nuclear Industry Events